FDA Approved: TABRECTA — Supplemental Application (Novartis Pharmaceuticals Corporation)

View source ↗

Summary

The FDA approved a supplemental application for Tabrecta (capmatinib) from Novartis Pharmaceuticals Corporation, authorizing changes to its labeling.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-small Cell Lung Cancer

Drugs mentioned

• Tabrecta (Capmatinib)

Snippet

SUPPL AP for TABRECTA (CAPMATINIB)